Adding low-dose cyclosporin A to parenteral gold therapy in rheumatoid arthritis: A double-blind placebo-controlled study

British Journal of Rheumatology

Volumn 35, Issue 11, 1996, Pages 1142-1149

  Bendix, G ^a   Bjelle, A ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Arthritis; Combination; Cyclosporin A; Drug therapy; Gold sodium thiomalate; Rheumatoid

Indexed keywords

ANTIRHEUMATIC AGENT; AUROTHIOMALATE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; POTASSIUM ION;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYANOCOBALAMIN DEFICIENCY; DOUBLE BLIND PROCEDURE; FEMALE; GOITER; GYNECOMASTIA; HEALTH STATUS; HUMAN; HYPERKALEMIA; HYPERURICEMIA; HYPOMAGNESEMIA; INTOXICATION; INTRAMUSCULAR DRUG ADMINISTRATION; KIDNEY FUNCTION; LOW BACK PAIN; LYMPHADENOPATHY; MALE; ORAL DRUG ADMINISTRATION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; WEIGHT REDUCTION;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CYCLOSPORINE; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; GOLD; GOLD SODIUM THIOMALATE; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLACEBOS;

EID: 0029951766     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986;29:706-14.
2. Pincus T. The paradox of effective therapies but poor long-term outcomes in rheumatoid arthritis. Semin Arthritis Rheum 1992;21(suppl.):2-15.
3. Scott DL, Symmons DPM, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: Results after 20 years. Lancet 1987;i:1108-11.
4. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
5. Kushner I, Dawson NV. Aggressive therapy does not substantially alter the long-term course of rheumatoid arthritis. So what else is new? Rheum Dis Clin North Am 1993;19:163-72.
6. Wilske KR. Inverting the therapeutic pyramid: observations and recommendations on new directions in rheumatoid arthritis therapy based on author's experience. Semin Arthritis Rheum 1993;23(suppl. 1): 11-8.
7. Thompson PW, Kirwan JR, Barnes CG. Practical results of treatment with disease-modifying antirheumatoid drugs. Br J Rheumatol 1985;24:167-75.
8. Situnayake RD, Grindulis KA, McConkey B. Long term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis 1987;46:177-83.
9. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
10. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
11. Bendix G, Bjelle A. A 10-year follow-up of parenteral gold therapy in RA patients. Ann Rheum Dis 1996;55:169-76.
12. Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. Arthritis Rheum 1994;37:1487-91.
13. Paulus HE. The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis. Arthritis Rheum 1990;33:113-20.
14. Paulus HE. Protocol development for combination therapy with disease-modifying antirheumatic drugs. Semin Arthritis Rheum 1993;23(suppl. 1):19-25.
15. Boers M, Ramsden M. Long acting drug combinations in rheumatoid arthritis: a formal overview. J Rheumatol 1991;18:316-24.
16. Williams HJ. Combination second-line therapy for rheumatoid arthritis. Br J Rheumatol 1994;33:603-4.
17. Furst DE, Clements PJ. Pharmacologic approaches. SAARDs-II Section 8:13. In: Klippel JH, Dieppe PA, eds. Rheumatology. London: Mosby, 1994:1-8.
18. Jaffe IA. Combination therapy of rheumatoid arthritis -rationale and overview. J Rheumatol 1990;17(suppl. 25):24-7.
19. McCarty DJ. Personal experience in the treatment of seropositive rheumatoid arthritis with drugs used in combination. Semin Arthritis Rheum 1993;23:42-9.
20. Wilke WS, Sweeney TJ, Calabrese LH. Early, aggressive therapy for rheumatoid arthritis: concerns, descriptions, and estimate of outcome. Semin Arthritis Rheum 1993;23:26-41.
21. Sievers K, Hurri L. Combined therapy of rheumatoid arthritis with gold and chloroquine. I. Evaluation of therapeutic effect. Acta Rheum Scand 1963;9:48-55.
22. Bitter T. Combined disease-modifying chemotherapy for intractable rheumatoid arthritis. Clin Rheum Dis 1984;10:417-28.
23. Singleton PT, Cervantes AG. Chrysotherapy and concomittant use of antimalarial drugs in rheumatoid arthritis. In: 5th SEAPAL Congress of Rheumatology, Bangkok, January 1984:12 (Abstract).
24. Dawes PT, Sheeran TP, Fowler PD, Shadforth MF. Improving the response to gold or d-penicillamine by addition of sulphasalazine. A pilot study in 25 patients with rheumatoid arthritis. Clin Exp Rheumatol 1987;5:151-3.
25. Farr M, Kitas G, Bacon PA. Sulphasalazine in rheumatoid arthritis: combination therapy with D-penicillamine or sodium aurothiomalate. Clin Rheumatol 1988;7:242-8.
26. Brawer AE. The combined use of oral methotrexate and intramuscular gold in rheumatoid arthritis. Arthritis Rheum 1988;31(suppl.):R10 (Abstract).
27. Scott DL, Dawes PT, Tunn E et al. Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: A prospective, randomized, placebo-controlled study. Br J Rheumatol 1989;28:128-33.
28. Yasuda M, Sakai K, Oribe M et al. Efficacy of additive DMARD therapy in patients with rheumatoid arthritis. Double blind controlled trial using bucillamine and placebo with maintenance doses of gold sodium thiomalate. J Rheumatol 1994;21:44-50.
29. McKenna F, Hopkins R, Hinchcliffe KP, Bird HA, Wright V. Gold and penicillamine, alone and in combination in active rheumatoid arthritis. In: XVIth International Congress of Rheumatology, Sydney, Australia, May 1985:221(Abstract).
30. Rau R. Nutzen und Risiko der Kombinationstherapie Methotrexate und Gold. Z Rheumatol 1992;51(suppl. 2):31-2.
31. Porter DR, Capell HA, Hunter J. Combination therapy in rheumatoid arthritis - no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy. J Rheumatol 1993;20:645-9.
32. Bensen W, Tugwell P, Roberts RM et al. Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies). J Rheumatol 1994;21:2034-8.
33. Tozman ECS, Gottlieb NL. Adverse reactions with oral and parenteral gold preparations. Med Toxicol 1987;2:177-89.
34. Dijkmans BAC, van Rijthoven AWAM, Goei The HS, Boers M, Cats A. Cyclosporine in rheumatoid arthritis. Semin Arthritis Rheum 1992;22:30-6.
35. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
36. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949;140:659-62.
37. Pinals RS, Masi AT, Larsen RA, The Subcommittee for Criteria of Remission in RA of the ARA Diagnostic and Therapeutic Criteria Comittee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
38. Ritchie DM, Boyle JA, McInnes JM et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;37:393-406.
39. Huskisson EC. Visual analogue scales. In: Melzack R, ed. Pain measurement and assessment. New York: Raven Press, 1983:33-7.
40. Nordenskiöld UM, Grimby G. Grip force in patients with rheumatoid arthritis and fibromyalgia and in healthy subjects. A study with the Grippit instrument. Scand J Rheumatol 1993 ;22:14-9.
41. Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 1988;17:263-71.
42. Archenholtz B, Bjelle A. Evaluation of a Swedish version of a new version of the Arthritis Impact Measurement Scales (AIMS2). In preparation.
43. Gudmundsson M, Bjelle A. Viscosity of plasma and blood in rheumatoid arthritis. Br J Rheumatol 1993;32:774-9.
44. Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis 1988;47:127-33.
45. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand 1940;17:172-88.
46. Bradley JW. Fisher's method of randomization. In: Bradley JW. Distribution-free statistical tests. London: Prentice-Hall, 1968:68-86.
47. Odén A, Wedel H. Arguments for Fisher's permutation test. Ann Statist 1975;3:518-20.
48. Maxwell AE. Analyzing qualitative data. London: Methuen, 1961.
49. Anderson JJ, Felson DT, Meenan RF, Williams HJ. Which traditional measures should be used in rheumatoid arthritis clinical trials? Arthritis Rheum 1989;32:1093-9.
50. Bellamy N, Watson Buchanan W. Assessment of antirheumatic activity in man. Baillière's Clin Rheumatol 1990;4:433-65.
51. Forre O, Norwegian Arthritis Study Group. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Arthritis Rheum 1994;37:1506-12.
52. Tugwell P, Bombardier C, Gent M et al. Low-dose cyclosporin vs placebo in patients with rheumatoid arthritis. Lancet 1990;335:1051-5.
53. Hazes JMW, Hayton R, Burt J, Silman AJ. Consistency of morning stiffness: An analysis of diary data. Br J Rheumatol 1994;33:562-5.
54. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
55. Cohen DJ, Appel GB. Cyclosporine: Nephrotoxic effects and guidelines for safe use in patients with rheumatoid arthritis. Semin Arthritis Rheum 1992;21(suppl. 3): 43-8.
56. Altman R. Double blind, controlled study of cyclosporin A in 244 patients with refractory rheumatoid arthritis. Rev Esp Reumatol 1993;20(suppl. 1):147 (Abstract).
57. van Rijthoven AWAM, Dijkmans BAC, Goei The HS et al. Comparison of cyclosporine and d-penicillamine for rheumatoid arthritis: A randomized, double blind, multicenter study. J Rheumatol 1991;18:815-20.
58. Krüger K, Schattenkirchner M. Comparison of Cyclosporin A and azathioprine in the treatment of rheumatoid arthritis - results of a double-blind multicentre study. Clin Rheumatol 1994;13:248-55.
59. Landewé RBM, Goei The HS, van Rijthoven AWAM, Breedveld FC, Dijkmans BAC. A randomized, double-blind, 24-week controlled study of low-dose cyclosporine vs chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994;37:637-43.
60. Tugwell P, Pincus T, Yocum D et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.